Subscribe

|Articles|June 26, 2015

GSK to Sell Legacy Vaccines to Pfizer

June 26, 2015.

GlaxoSmithKline has announced that it will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals. The €115m sale is subject to final European Commission approval, other regulatory approvals, and other customary closing conditions and is expected to close before the end of the year.

Source: GSK

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Stock.adobe.com

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda

ByNicholas Jacobus

October 14th 2025

Shauna Tetrald, PhD

Challenges of Positioning an Ultra-Sensitive Platform

ByNicholas Jacobus,Shana Tetrault, PhD

October 9th 2025

Pharmaceutical Executive

Translating Complex Scientific Findings into Actionable Insights

ByNicholas Jacobus,Shana Tetrault, PhD

October 8th 2025

Anna Vuolo

More Than an Algorithm: Building Medical AI

October 3rd 2025

AI and R&D: From the Eyes of an Entrepreneur

ByMichael Christel

October 2nd 2025

Trending on PharmExec

Johnson and Johnson Reveals Plan to Separate Orthopaedics Business

The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.

The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma

Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil

© 2025 MJH Life Sciences^®

All rights reserved.